gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin data mdco t-cell tx collabor
highlight week august august mdco buy chardan top pick announc
first pivot phase studi rnai therapeut inclisiran met primari secondari endpoint efficaci
consist phase phase ii studi safeti least favor phase ii
open-label extens studi mdco plan present detail data late-break scienc session
esc congress pari septemb edt unrat data publish
jama ophthalmolog phase ii investigator-sponsor trial choroideremia
base gene therapi gt mean chang best-correct visual acuiti bcva
treat eye control eye month sd sd
patient achiev improv etdr score respect public also summar
data trial immat privat announc
strateg collabor option agreement celgen corpor unrat develop t-cell receptor
engin cell therapi tcr-t cancer immunotherapi agreement celgen exclus
option tcr-t target pay immat mm up-front plu mm potenti futur payment
licens product adaptimmun unrat announc collabor noile-immun privat
co-develop next gener spear t-cell product secret use noile-immun prime
prolifer induc migrat enhanc technolog adaptimmun make up-front payment mileston
payment noile-immun mm compani aim begin human test program
look forward septemb septemb august septemb european societi cardiolog
esc annual congress continu pari agenda includ kol symposia repres alnylam
buy mdco novarti pharma ag unrat septemb mdco host confer call
edt discuss result present esc septemb european amyloidosi allianc meet
take place berlin agenda featur repres akcea therapeut unrat
intellia buy unrat septemb societi studi
inborn error metabol ssiem host annual symposium rotterdam netherland program
includ repres genethon privat unrat
unrat septemb oxford biomedica unrat report earn et
weekli price move vivo genet medicin aav srna mrna vivo gene edit
 mrna mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
cbio buy marzaa catalyst may becom phase compani august amusa
catalyst bioscienc provid updat marzaa marzeptacog alfa activ compani next-gener
factor viia fviia kol luncheon new york
overal believ view express kol luncheon marzaa support view tangibl
credibl marzaa particular may show util area hemophilia bleed disord higher
unmet medic need see cbio pois gener invest return move away sub-cash
valuat execut catalyst movement marzaa phase clinic develop
pleas refer import disclosur inform regul analyst certif found page report
mdco buy import phase meet endpoint august amusa
buy pt posit top-line data inclisiran studi august naka
medicin compani chardan top pick announc pivot phase studi met
primari secondari endpoint efficaci consist phase ii studi safeti least
favor phase ii open-label extens studi us import posit
support bn inclisiran estim consolid bn mdco
mdco plan present detail efficaci safeti toler data late-break scienc session
european societi cardiolog esc congress pari septemb edt compani also
plan host confer call septemb edt
result pivot phase trial posit mdco plan submit nda inclisiran fda
inclisiran ema
neutral feedback note caution august amusa
respond feedback august research express caution
go interim data cohort optic phase trial intravitr ivt aav-
base gene therapi gt due septemb
affirm mention risks/view de-emphasize import risk previous note
also present view upsid risk keep us neutral rate less caution due
recent re-pric anti-vegf market perhap largest opportun current target aav-
base success ivt could take bn market cap rang
genet medicin news august august
bch publish crispr gene edit approach treat triple-neg breast cancer august
yale publish rnai approach target tgf receptor treat atherosclerosi august
cibir publish exosome-deliv shrna approach treat parkinson diseas august
adap unrat announc agreement noile-immun privat spear t-cell immunotx august
adaptimmun announc collabor agreement noile-immun compani co-
develop next-gener spear t-cell product compani aim begin human test program
collabor bring togeth noile-immun prime technolog adaptimmun spear t-cell develop
spear t-cell secret secret may increas t-cell prolifer
traffick may enhanc anti-tumor activ cancer patient prime technolog alreadi test
augment car-t cell activ collabor takeda unrat
agreement adaptimmun world-wide right develop commerci product aris
collabor adaptimmun make up-front payment mileston payment noile-immun
mm noile-immun also entitl mid-singl digit royalti net sale
unrat announc licens agreement csl ax unrat lentiviru produc cell line august
unrat announc gsk unrat exercis option licens aso program hbv august
announc posit result phase ii trial gsk exercis
option licens ioni antisens oligonucleotid aso program treatment patient chronic hepat
 viru hbv full result phase ii trial present upcom medic confer
agreement ioni entitl receiv mm licens fee mileston payment includ
mm up-front licens fee ioni also entitl receiv tier low doubl digit royalti net sale gsk
respons futur develop commerci program
buy receiv mm unrat initi piib combo trial rnai tx hbv august
arrowhead announc janssen johnson johnson compani initi patient dose phase
iib trial combin regimen includ rnai therapeut formerli aro-hbv and/or
capsid assembl modul nucleosid analog treatment hbv
phase iib trial enrol patient random receiv week treatment connect
initi patient dose arrowhead receiv mm mileston payment janssen
immat privat announc collabor celg unrat t-cell cancer immunotherapi august
immat announc strateg collabor option agreement celgen develop tcr-t cancer
immunotherapi use immat xpresid technolog xceptor discoveri engin platform
page
agreement celgen make up-front payment immat mm plu mm futur
payment licens product tier royalti net sale celgen obtain right licens
program immat respons develop lead select stage point celgen
may opt-in assum develop commerci cost go forward
hifibio privat announc close mm seri singl cell-bas antibodi platform august
 minnesota publish autolog cell therapi august
case western publish hydrogel approach improv sirna deliveri august
lumc publish crispr/hdr platform engin immunoglobulin domain hybridoma august
viralgen privat receiv cgmp certif ema aav manufactur august
edigen privat announc compani chang name august
cbio buy announc departur cfo fletcher payn august
griffith univers publish approach target hpv oncogen tumor august
ortx unrat announc appoint dr john curnutt board director august
carsgen tx privat receiv fda orphan drug design anti-bcma car-t tx mm august
compani mention report
page
select catalyst genet medicin coverag
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi patient dose brillianc phase i/ii trial
report result phase i/ii ignit dmd trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
present top-lin data phase i/iia clinic trial wet
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
initi phase i/ii trial parkinson diseas mutat
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
rituximab report preliminari phase cohort data r/r nhl
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end august vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet therapytickerratingccm ptupsideclosechang changemc mm gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareabeona genet privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighsharecrispr privat vivogen edit companiesbeam therapeut egenesi excis therapeut exon therapeut feldan therapeut recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
